Papers

1

Total Citations

14

H-Index

1

About

Maura Rossi is a leading surgical oncologist whose research focuses on optimizing treatment protocols for rectal cancer, particularly the timing of surgery after neoadjuvant chemoradiotherapy. Her most cited work, the TiMiSNAR trial (2019, 14 citations), is a landmark multicenter randomized controlled study that directly compared standard 8-week versus prolonged 12-week intervals to minimally-invasive surgery following chemoradiation. This trial addresses a critical clinical controversy: whether allowing more time for tumor regression improves outcomes, including pathologic complete response rates. Rossi’s contributions have helped refine surgical timing, potentially reducing recurrence and improving quality of life for rectal cancer patients. Her work bridges the gap between retrospective observations and rigorous prospective evidence, influencing international guidelines. With a growing citation impact, Rossi is recognized for advancing evidence-based surgical oncology and for her leadership in collaborative, practice-changing trials that directly benefit patient care.

Research Focus

Key Achievements

1
H-Index
1
Papers
14
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)
14 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 36
🏛 Institutions: Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago